


TB Nurse Case Management

The Marathon



Denise Dodge RN
April 11, 2013

VDH VIRGINIA
DEPARTMENT
OF HEALTH
Protecting You and Your Environment


Objectives

- Describe 3 critical nurse case management decision points during TB treatment
- Explain the rationale for monitoring bacteriology culture conversion
- List 4 ongoing TB nurse cases management interventions that may improve treatment outcomes
- Explain criteria used for determining treatment completion

VDH VIRGINIA
DEPARTMENT
OF HEALTH
Protecting You and Your Environment

Sprint vs Marathon

3



Continuation Phase Challenges

4

- Monitoring treatment effectiveness
- Determining treatment regimens
- Managing adverse events
- Managing barriers to adherence
- Calculating treatment completion




Sputum Smear/Culture Conversion

5

Question Answered	Method	
Diagnosis	3 consecutive sputum upon intake	Healthcare worker observed Prefer early morning
Smear Conversion/ Initial Response to Treatment	Sputum every 1 to 2 weeks depending on smear results	After first negative smear, collect two more within days
Culture Conversion/ Test of Cure	Collect a minimum of 3 sputum specimens throughout the month	Continue collection until 2 consecutive cultures are negative
Treatment Failure	Collect 3 sputum specimens	Intervene as needed
Treatment Length	Collect 3 sputum between the 55 th and 60 th day after treatment started	Minimum of 3 specimens at least 8 hours apart INDUCE IF NECESSARY!!!

Decision Point – 8 weeks/ 60 days

6



Sputum Culture Conversion – 60 days!

7

Question Answered	Method	
Diagnosis	3 consecutive sputum upon intake	Healthcare worker observed Prefer early morning
Smear Conversion/ Initial Response to Treatment	Sputum every 1 to 2 weeks depending on smear results	After first negative smear, collect two more within days
Culture Conversion/ Test of Cure	Collect a minimum of 3 sputum specimens throughout the month	Continue collection until 2 consecutive cultures are negative
Treatment Failure	Collect 3 sputum specimens	Intervene as needed
Treatment Length	Collect 3 sputum between the <u>55th and 60th</u> day after treatment started	Minimum of 3 specimens at least 8 hours apart INDUCE IF NECESSARY!!!

What should happen **at/by** 8 weeks?

8



- Decide if suspect is a case of TB or not?
 - Culture confirmed, Clinical, Provider
 - Surveillance Team, Bill and Tim
- Plan to look for culture conversion
- Susceptibilities
- Recognize slow response
- Be alert for 'Hit the wall' behavior



TB or Not TB?...That is the question!


9

- Case Definition criteria
 - Organism ID
 - DNA probe
 - Löwenstein-Jensen media
 - Nucleic Acid Amplification Test
 - Mycobacterium Direct Test (DCLS)
 - Polymerase Chain Reaction (Other labs)
 - TST or IGRA result
 - Chest x-ray
 - Clinical evidence




Importance of culture conversion

10




Importance of culture conversion

11




Importance of sputum conversion

12




Importance of sputum conversion

13



Importance of sputum conversion


14



Culture Negative Pulmonary Tuberculosis

Treatment of Tuberculosis, MMWR 2003, p7, fig. 2


15



Culture Negative Pulmonary Tuberculosis

Treatment of Tuberculosis, MMWR 2003, p7, fig. 2


16



Culture Negative Pulmonary Tuberculosis

Treatment of Tuberculosis, MMWR 2003, p7, fig. 2

17



Summary – Sputum collection

18

At least one Health care worker observed
Early morning to improve quality

- Initially - 3 consecutive specimens
- One sample every 2 weeks after initial series of 3
 - May be done in one week if smear not strongly positive
- After first negative smear, collect 2 additional within a few days
 - Repeat in 1 week if any smears are positive
- Collect 3 specimens between days 55 - 60**
- Continue collecting monthly until 2 consecutive cultures are negative**

Susceptibilities

19

- Available 2 – 4 weeks after isolate is identified
 - Should be available 6 – 8 weeks after specimen collection
 - Do not hesitate to call lab
- Helps with determining if treatment is appropriate
- Pan sensitive – Discontinue Ethambutol (with order)
- If resistance is present...




YIKES!

Resources for Managing Drug Resistance

20

- Drug-Resistant Tuberculosis, 2nd Ed.
Francis j. Curry National TB Center, <http://www.currytbcenter.ucsf.edu/>

- MDR TB Care Plan
Characteristics of Second Line Drugs
Heartland National TB Center
<http://www.heartlandntbc.org/>



Documentation - Bacteriology Flow sheet

21

Keeping it all in order

Virginia Department of Health
Bacteriology Flow Sheet

Name _____ DOB _____

DATE COLLECTED							
SPECIMEN TYPE							
SPECIMEN #							
SMEAR RESULT							
MTD/NAA RESULT							
CULTURE RESULT							
NAME OF LAB							

Circle and note date of smear conversion and date of culture conversion. Date of smear conversion _____
Date of culture conversion _____

DRUG SUSCEPTIBILITY TESTING: *Mycobacterium tuberculosis* cultures and isolates only

Initial Susceptibility Results			Additional Susceptibility Results		
Date Collected:	Culture or Isolate #:		Date Collected:	Culture or Isolate #:	
Laboratory			Laboratory		
DRUG	SENSITIVE	RESISTANT	DRUG	SENSITIVE	RESISTANT
Isoniazid			Isoniazid		
Rifampin			Rifampin		
Ethambutol			Ethambutol		
Pyrazinamide			Pyrazinamide		

Documentation - Bacteriology Flow sheet

22

Keeping it all in order

Virginia Department of Health
Bacteriology Flow Sheet

Name _____ DOB _____

DATE COLLECTED	2/1/13						
SPECIMEN TYPE	Sputum						
SPECIMEN #							
SMEAR RESULT							
MTD/NAA RESULT							
CULTURE RESULT							
NAME OF LAB	DCLS						


- Date collected:
 - is not the date you picked it up
 - is not the date the report was received
- Always note the source/specimen type
- Where it was sent will help you find it in the future!

Documentation - Bacteriology Flow sheet

23

Virginia Department of Health
Bacteriology Flow Sheet

Name _____ DOB _____



DATE COLLECTED	2/1/13						
SPECIMEN TYPE	Sputum						
SPECIMEN #	12345						
SMEAR RESULT	3+						
MTD/NAA RESULT							
CULTURE RESULT							
NAME OF LAB	DCLS						

First report


- Specimen number: this may be the only way to differentiate between specimens
- Smear positivity is normally reported, don't just record positive unless that is all you have
- Many reports to follow

Documentation - Bacteriology Flow sheet

24

Virginia Department of Health
Bacteriology Flow Sheet

Name _____ DOB _____




DATE COLLECTED	2/1/13						
SPECIMEN TYPE	Sputum						
SPECIMEN #	12345						
SMEAR RESULT	3+						
MTD/NAA RESULT	Positive						
CULTURE RESULT							
NAME OF LAB	DCLS						

Nucleic Acid Amplification

- First specimen only
- Within days of receiving smear result
- This is not a culture but is acceptable for reporting
- Susceptibilities will not be started yet, need isolate (culture)

Documentation - Bacteriology Flow sheet

25



Virginia Department of Health
Bacteriology Flow Sheet

Name _____ DOB _____

DATE COLLECTED	2/1/13						
SPECIMEN TYPE	Sputum						
SPECIMEN #	12345						
SMEAR RESULT	3+						
MTD/NAA RESULT	Positive						
CULTURE RESULT	Mtb						
NAME OF LAB	DCLS						

Culture Results

- Will take 6 – 8 weeks
- AFB + culture may be reported first, without ID
- Several preliminary reports will arrive
- After the culture is reported, the susceptibilities will now begin on first positive *M.tb* specimen

Documentation - Bacteriology Flow sheet

26

Treatment initiated in hospital 1/20/13

Organize data in chronological order

Towards the end of treatment be sure all final lab results are back

3/16/13 – 3/21/13

Virginia Department of Health
Bacteriology Flow Sheet

Name _____ DOB _____

DATE COLLECTED	2/1/13	2/2/13	2/3/13	2/12/13	2/13/13	2/21/13	3/10/13
SPECIMEN TYPE	Sputum	Sputum	Sputum	Sputum	Sputum	Sputum	Sputum
SPECIMEN #	12345	12346	12351	12411	12434	12577	12901
SMEAR RESULT	3+	1+	2+	neg	2+	1+	(neg)
MTD/NAA RESULT	Positive	-----	-----	-----	-----	-----	-----
CULTURE RESULT	Mtb	Mtb	Mtb	Mtb	Mtb	Mtb	Mtb
NAME OF LAB	DCLS	DCLS	DCLS	DCLS	DCLS	DCLS	DCLS

DATE COLLECTED	3/12/13	3/13/13	3/16/13	3/17/13	3/20/13	3/27/13	4/10/13
SPECIMEN TYPE	Sputum						
SPECIMEN #	13326	13346	13416	13427	13469	13701	14746
SMEAR RESULT	neg						
CULTURE RESULT	Mtb	Mtb	Mtb	(neg)	neg	neg	neg
NAME OF LAB	DCLS						

DATE COLLECTED	5/10/13						
SPECIMEN TYPE	Sputum						
SPECIMEN #	15399						
SMEAR RESULT	neg						
CULTURE RESULT							
NAME OF LAB	DCLS						

Documenting Susceptibilities

27

Circle and note date of smear conversion and date of culture conversion.

Date of smear conversion
Date of culture conversion

3/10/13
3/17/13

DRUG SUSCEPTIBILITY TESTING: *Mycobacterium tuberculosis* cultures and isolates only

Initial Susceptibility Results			Additional Susceptibility Results		
Date Collected:	2/1/13	Culture or Isolate #: 12345	Date Collected:		Culture or Isolate #:
Laboratory			Laboratory		
DRUG	SENSITIVE	RESISTANT	DRUG	SENSITIVE	RESISTANT
Isoniazid	X		Isoniazid		
Rifampin	X		Rifampin		
Ethambutol	X		Ethambutol		
Pyrazinamide	X		Pyrazinamide		

Report results to treating physician
within 24 hours of receiving the report

Slow Response – 4 to 6 weeks of treatment

28

- Definition:
 - Sputum smear (+) not decreasing**
 - adequate decrease is:
 - 4+ to 2+
 - 3+ to 1+ or,
 - 2+ or 1+ to smear negative
 - No improvement in TB symptoms**
 - no weight gain
 - no reduction in cough
 - persistent fever, or
 - worsening of chest x-ray if performed

Slow Response

29

WHY	Adherence	Treatment Regimen	Drug Resistance	Malabsorption
	ETOH/Other substances	Wrong meds	Malabsorption	Diabetes
	Number of pills	Wrong frequency	Wrong dosage	Cachexia
	Side Effects	Wrong dosage	No DOT	HIV
	Priorities	Wrong diagnosis	Wrong drug for resistance pattern	Chron's disease
	Cultural beliefs	Drug interactions	Wrong Regimen	Gastric Surgery
	Drug interaction		Country of origin	Cystic Fibrosis
	Forgetful			Food interaction
	Willful refusal			
	No DOT			

Serum Drug Levels

30

- Diabetics at 2 weeks automatically
- Others, if treatment failure is apparent
 - Be sure your sputum results are clearly documented
 - Ensure DOT
 - Assess for clinical improvement: weight, temperature, reported improvement, lessened cough, increase energy
 - CXR does not improve as quickly as sputa and clinical status
- Follow VDH Policy
 - Recommendations on report are often different than VDH policy!
 - Must consult with TB physicians for intervention

Barriers to Adherence - Patient

32

- Complacency
 - Feels better
 - Reduced fear
 - Want freedom
 - Back to Normal
 - Risky Behaviors
 - Recalcitrant




Address non-adherence promptly

Interventions for Barriers to Adherence

33

- HIP Program
- Mental health referral
- Substance abuse services
- Food pantries
- Meals on Wheels
- Transportation
- Translation services



Barriers to Care - Organization



34

- Missed communication opportunities
- Calm after the storm
- Multiple programs, multiple responsibilities
- Perceived low priority
- Time constraints
- Poor understanding of TB NCM
- Available resources

Barriers to Adherence - Contacts

35

- Apathetic
 - Perceived health risk
 - Forgot
 - Fearful
 - Cost




VDH VIRGINIA
DEPARTMENT
OF HEALTH
Protecting You and Your Environment

36

Treatment Regimens

Treatment Regimens

37



Treatment Regimens

38

- Continuation phase
 - Susceptibility results
 - Discontinue Ethambutol with order
 - Adjust other drugs as appropriate
 - Rifampin resistance - much longer regimen 12 – 18 months
 - Toxicity/Intolerance = Proxy drug resistance
 - No improvement, NTM?, Sarcoid?, Cancer? = d/c meds
 - PZA and the continuation phase

Doses of PZA in Treatment

39

- Must complete PZA doses for 6 month regimen
 - 7 days/week for 8 weeks – 56 doses
 - 5 days/week for 8 weeks – 40 doses
 - 7 days/week x 2 weeks, then twice weekly for 6 weeks – $14 + 12 = 26$ doses
 - 5 days/week x 2 weeks, then twice weekly for 6 weeks – $10 + 12 = 22$ doses
 - 3 times/week for 8 weeks: 24 doses

Monthly Clinical Monitoring

40


- Nurse or physician
 - Do in home at least every other month
 - Assess for response to treatment of potential medication side effects
 - Assess for barriers to care
 - Blood work frequency: required as needed, not as routine!
 - Visual acuity and color discrimination: Ethambutol
 - Auditory assessment: injectables

Reactions requiring immediate report

41

Hold medication

- Jaundice
- Dark urine
- Vomiting
- Abdominal pain
- Fever
- Visual changes
- Marked rash



Reactions requiring a report in 24 hrs


42

Do not hold without an order

- Anorexia
- Nausea
- Malaise
- Peripheral neuropathy
- Rashes

Addressing treatment complaints

43



- Common, manageable side effects
 - Fatigue
 - Nausea
 - Rash without hives
 - Headache
 - Tyramine reaction
 - Peripheral neuritis
 - Arthralgias
 - Sunburn

Common problems/simple solutions (1)

44

- Fatigue
 - take meds at the end of the day
 - Reassure should improve with time
- GI symptoms/dyspepsia
 - Light meal
 - H₂ antagonists



Common problems/simple solutions (2)

45

Rash

Questions to Ask

- Has this happened in the past?
- When does it happen?
- Localized or generalized?
- Itchy? Painful? Hot? Dry?



- Do not presume it is an allergic reaction
- Topical treatment: corticosteroids, topical anesthetics or antihistamines
- Oral antihistamines
- Moisturizing may help


VDH VIRGINIA
DEPARTMENT
OF HEALTH
Protecting You and Your Environment

Common problems/simple solutions (3)

46

Headache

- Take medication later in the day
- Improve nutritional intake



Tyramine reaction

- Self limiting: headache, palpitations, upper body flushing and itching,
- Consider food preferences
- Not an allergic reaction but consider antihistamines

VDH VIRGINIA
DEPARTMENT
OF HEALTH
Protecting You and Your Environment

Common problems/simple solutions (4)


47

- Peripheral Neuritis
 - Diabetic?
 - Vitamin B6/pyridoxine: 25, 50, 75, 100 and beyond
- Arthralgias
 - Other co-morbidity
 - Likely Rifamycin? (generalized)
 - Likely PZA? (joints)
 - Menopause?
 - Mild analgesic

Common problems/simple solutions (5)

48

- Sunburn
 - Stay out of sun, **HOWEVER**, may not be as easy
 - Wear protective cotton clothing
 - Use sun block!



Interruptions in Treatment

49

- In continuation phase
 - If less than 80% complete, resume, count doses; collect sputa
 - If more than 80% complete, may need no further treatment
 - Always check overall timeframes for regimen and count accurately

Life happens!

50

- Going back to work
 - DOT Flexibility – Location, Time, Frequency
- Moving
 - Working with districts within Virginia
 - Reporting district maintains case management responsibility
 - Working district communicates status
 - Provide labs, DOT records
- Family/Friend difficulty
 - Living arrangements
 - Broken relationships

Relocating to another district or state

51

- Communicate with new location
- Open lines of communication to foster free flow of information
- **YOU** remain responsible for managing treatment course of your patient, even if cared for elsewhere
- Interstate: Interjurisdictional transfer required
 - Complete and forward to TB control by FAX



VDH VIRGINIA
DEPARTMENT
OF HEALTH
Protecting You and Your Environment

You've Broken through!

52



VDH VIRGINIA
DEPARTMENT
OF HEALTH
Protecting You and Your Environment


TB Treatment Regimens

TABLE 2. Drug regimens for culture-positive pulmonary tuberculosis caused by drug-susceptible organisms

Regimen	Initial phase		Continuation phase			Range of total doses (minimal duration)	Rating* (evidence)†		
	Drugs	Interval and doses‡ (minimal duration)	Regimen	Drugs	Interval and doses‡§ (minimal duration)		HIV*	HIV*	
1	INH RIF PZA EMB	Seven days per week for 56 doses (8 wk) or 5 d/wk for 40 doses (8 wk) [¶]	1a	INH/RIF	Seven days per week for 126 doses (18 wk) or 5 d/wk for 90 doses (18 wk) [¶]	182–130 (26 wk)	A (I)	A (II)	
			1b	INH/RIF	Twice weekly for 26 doses (18 wk)		92–76 (26 wk)	A (I)	A (II)*
			1c**	INH/RPT	Once weekly for 18 doses (18 wk)		74–58 (26 wk)	B (I)	E (I)
2	INH RIF PZA EMB	Seven days per week for 14 doses (2 wk), then twice weekly for 10 doses (6 wk) or 5 d/wk for 10 doses (2 wk) [¶] then twice weekly for 12 doses (6 wk)	2a	INH/RIF	Twice weekly for 36 doses (18 wk)	62–58 (26 wk)	A (II)	B (II)*	
			2b**	INH/RPT	Once weekly for 18 doses (18 wk)		44–40 (26 wk)	B (I)	E (I)
3	INH RIF PZA EMB	Three times weekly for 24 doses (8 wk)	3a	INH/RIF	Three times weekly for 54 doses (18 wk)	78 (26 wk)	B (I)	B (II)	
4	INH RIF EMB	Seven days per week for 56 doses (8 wk) or 5 d/wk for 40 doses (8 wk) [¶]	4a	INH/RIF	Seven days per week for 217 doses (31 wk) or 5 d/wk for 155 doses (31 wk) [¶]	273–195 (39 wk)	C (I)	C (II)	
			4b	INH/RIF	Twice weekly for 62 doses (31 wk)		118–102 (39 wk)	C (I)	C (II)

Completing treatment

55



Counting Doses

56

Guidelines for Determination of Completion of Treatment

- Counts doses observed, not the calendar
 - 2 month initial phase completed in 3 months
 - 6 months within 9 months
 - 9 months within 12 months
 - Non-standard regimens require individualized approach

DOT

57

- Program standard
 - All doses DOT – DOT
 - No doses DOT – Self administered
 - Any doses self administered – DOT/self administered
 - Other health care facility - Assess quality of DOT
- Video Observed Treatment
- Exceptions
 - Patients not reported at the onset of treatment
 - Physician refusal

Adding it all up!

58

TB Case Completion /Discontinue Medicine Report

- Non DOT counted doses should be extremely rare
- Facility doses should only be counted if documentation is provided
- Detail any non-DOT counted doses or facility counted doses
- Initial phase must include 40 (or more) doses of PZA for a 6 month regimen
- The continuation phase begins at the 41st dose, even when 4 drugs are continued

Regimen	Days per week	Total doses	Number of weeks
Daily	7 days per week	56	8
*Weekday daily	5 days per week	40	8
Two weeks daily, then twice weekly	7 days/week for 2 weeks, then two times per week	14 daily doses, then 12 twice weekly doses (26 total doses)	8
*Two weeks weekday daily, then twice weekly	5 days /week for 2 weeks, then two times per week.	10 weekday daily doses, then 12 twice weekly doses (22 total doses)	8
Thrice weekly	3 times per week	24	8

Monitoring Changes to Therapy

59

- Assure drug susceptibility results are available before stopping any drugs
- 4 month regimen for culture negative pulmonary TB
- Review dose count if drug resistance
 - Count dose only if it is acceptable regimen
 - Consult with TB physician

Doing the Math for the Perfect Patient

60

Doses Required for Completion of Continuation Phase of Treatment
(Use for uncomplicated cases on INH/rifampicin regimens only. Not for use for cases on second line drugs)

Regimen	Days per week	Total doses	Number of weeks
Daily	7 days per week	126	18
Weekday daily	5 days per week	90	18
*Twice weekly	2 days per week	36	18
#Once weekly (INH/rifapentine regimen only)	1 day per week	18	18
~Thrice weekly	3 days per week	54	18

*DDP-TB recommended option except for patients with HIV infection.

DOT doses at 7 days per week regimen = _____ ÷ 7 = _____ weeks therapy

DOT doses at 5 days per week regimen = 40 ÷ 5 = 8 weeks therapy

DOT doses at 3 days per week regimen = _____ ÷ 3 = _____ weeks therapy

DOT doses at 2 days per week regimen = 36 ÷ 2 = 18 weeks therapy


DOT doses at 1 day per week regimen = _____ ÷ 1 = _____ weeks therapy

Add all the weeks of therapy above to calculate

TOTAL WEEKS OF THERAPY = 26

Completing Treatment - 9 months

61




- # DOT doses at 7 days per week regimen = _____ ÷ 7 = _____ weeks therapy
- # DOT doses at 5 days per week regimen = 40 ÷ 5 = 8 weeks therapy
- # DOT doses at 3 days per week regimen = _____ ÷ 3 = _____ weeks therapy
- # DOT doses at 2 days per week regimen = 62 ÷ 2 = 31 weeks therapy
- # DOT doses at 1 day per week regimen = _____ ÷ 1 = _____ weeks therapy

Add all the weeks of therapy above to calculate
 TOTAL WEEKS OF THERAPY = 39

Culture Negative - 4 months

62



- # DOT doses at 7 days per week regimen = _____ ÷ 7 = _____ weeks therapy
- # DOT doses at 5 days per week regimen = 40 ÷ 5 = 8 weeks therapy
- # DOT doses at 3 days per week regimen = _____ ÷ 3 = _____ weeks therapy
- # DOT doses at 2 days per week regimen = 16 ÷ 2 = 8 weeks therapy
- # DOT doses at 1 day per week regimen = _____ ÷ 1 = _____ weeks therapy

Add all the weeks of therapy above to calculate
 TOTAL WEEKS OF THERAPY = 16

**Virginia Department of Health
TB Case Completion /Discontinue Medicine Report
Fax to TB Control Program
804-371-0248**

Date form completed: _____

Name: _____ DOB: _____
PHN: _____ (phone number _____)

Date Therapy Stopped: _____ Reason Therapy Stopped
 Completed therapy
 Lost
 Uncooperative or refused
 Adverse treatment event
 Not TB
 Died
 Other (specify _____)

If died, indicate cause of death (select one) Date of Death: _____
 Related to TB disease
 Related to TB therapy
 Unrelated to TB disease
 Unknown

Reason therapy extended beyond 12 months (select all that apply)
 Rifampin resistant
 Adverse drug reaction
 Non-adherence
 Treatment failure
 Clinically indicated- other reasons
 Other (specify _____)

Dose counts (complete for ENTIRE treatment regimen whether provided in VA or not) Complete only those sections appropriate for each client based on drug order for treatment regimen. Non-DOT counted doses should be extremely rare. Facility doses should only be counted if facility documentation provided. Detail any non-DOT counted doses or facility counted doses in the space below.

DOT doses at 7 days per week regimen = _____ + 7 = _____ weeks therapy
 # DOT doses at 5 days per week regimen = _____ + 5 = _____ weeks therapy
 # DOT doses at 3 days per week regimen = _____ + 3 = _____ weeks therapy
 # DOT doses at 2 days per week regimen = _____ + 2 = _____ weeks therapy
 # DOT doses at 1 day per week regimen = _____ + 1 = _____ weeks therapy

Add all the weeks of therapy above to calculate
 TOTAL WEEKS OF THERAPY = _____

Send DOT records for review BEFORE stopping treatment If you need assistance with calculating doses

Jane Moore
 Debbie Staley
 Denise Dodge



Contact Investigation – Round 2

64

VIRGINIA DEPARTMENT OF HEALTH DIVISION OF TUBERCULOSIS (TB) CONTROL ~ TB CONTACT INVESTIGATION FORM (TB 502)					
WARD/REPORTED BY <i>Cecilia Boudreaux</i>	Case No. <i>804-864-7969</i>	Date Reported to HD <i>7/22/12</i>	Date CI Initiated <i>7/23/12</i>	Infectious Period Date Began: <i>3/1/12</i> Date Ended: <i>8/1/12</i>	
Type of Investigation: <input checked="" type="checkbox"/> Contact	Source Case	Type of Case/Support: <input checked="" type="checkbox"/> Primary Contact	Primary Contact Neg	Entrepreneurial	Clinical
Contact Name: (*) <i>John Boudreaux</i>	Priority <input checked="" type="checkbox"/> High <input type="checkbox"/> Med <input type="checkbox"/> Low	Hx of Prior (+) TST or TB <input checked="" type="checkbox"/> TB Disease Hx of prior Tx: Explain: <i>N/A</i>	LTBI Test Used: <input checked="" type="checkbox"/> TST <input type="checkbox"/> IGRA Round 1, Date tested: <i>7/24/12</i> Result: <i>1.8</i> mm of TST <i>N/A</i> Pos. Neg. Indeterminate/Borderline	CXR Date <i>8/30/12</i> Result: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Abnormal <input type="checkbox"/> Cavitory <input type="checkbox"/> Non Cav.	Case: Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> LTBI Tx Recommended: Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> If Yes: Tx Start: <i>9/1/12</i> Tx Stop: _____ Stop Reason: _____
DOB: <i>9/21/54</i> Race: <i>W</i> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Relationship: Household <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Spouse Last exposure date: <i>7/20/12</i>	Symptoms Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>		Round 2, Date tested: _____ Result: _____ mm of TST <i>N/A</i> Pos. Neg. Indeterminate/Borderline		Comments/Address if needed: <i>pt went to ER w/ I index, I index admitted to hospital 7/20/12</i>
Contact Name: (*) <i>Jason Boudreaux</i>	Priority <input checked="" type="checkbox"/> High <input type="checkbox"/> Med <input type="checkbox"/> Low	Hx of Prior (+) TST or TB <input checked="" type="checkbox"/> TB Disease Hx of prior Tx: Explain: <i>N/A</i>	LTBI Test Used: <input checked="" type="checkbox"/> TST <input type="checkbox"/> IGRA Round 1, Date tested: <i>7/24/12</i> Result: <i>0</i> mm of TST <i>N/A</i> Pos. Neg. Indeterminate/Borderline	CXR Date <i>N/A</i> Result: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Abnormal <input type="checkbox"/> Cavitory <input type="checkbox"/> Non Cav.	Case: Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> LTBI Tx Recommended: Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> If Yes: Tx Start: _____ Tx Stop: _____ Stop Reason: _____
DOB: <i>6/2/87</i> Race: <i>W</i> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Relationship: Household <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Son Last exposure date: <i>4/1/12</i>	Symptoms Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>		Round 2, Date tested: _____ Result: _____ mm of TST <i>N/A</i> Pos. Neg. Indeterminate/Borderline		Comments/Address if needed: <i>Last exposure date = 4/1/12 - one test is sufficient. No infection</i>
Contact Name: (*) <i>John Boudreaux Jr.</i>	Priority <input checked="" type="checkbox"/> High <input type="checkbox"/> Med <input type="checkbox"/> Low	Hx of Prior (+) TST or TB <input checked="" type="checkbox"/> TB Disease Hx of prior Tx: Explain: <i>N/A</i>	LTBI Test Used: <input checked="" type="checkbox"/> TST <input type="checkbox"/> IGRA Round 1, Date tested: <i>7/24/12</i> Result: <i>0</i> mm of TST <i>N/A</i> Pos. Neg. Indeterminate/Borderline	CXR Date <i>10/20/12</i> Result: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Abnormal <input type="checkbox"/> Cavitory <input type="checkbox"/> Non Cav.	Case: Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> LTBI Tx Recommended: Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> If Yes: Tx Start: <i>11/1/12</i> Tx Stop: _____ Stop Reason: _____
DOB: <i>2/14/80</i> Race: <i>W</i> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Relationship: Household <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Son Last exposure date: <i>6/20/12</i>	Symptoms Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>		Round 2, Date tested: <i>9/30/12</i> Result: <i>1.3</i> mm of TST <i>N/A</i> Pos. Neg. Indeterminate/Borderline		Comments/Address if needed: <i>Symptoms seen June, 20 further follow-up needed.</i>
Contact Name: (*) <i>Carol Hughes</i>	Priority <input checked="" type="checkbox"/> High <input type="checkbox"/> Med <input type="checkbox"/> Low	Hx of Prior (+) TST or TB <input checked="" type="checkbox"/> TB Disease Hx of prior Tx: Explain: <i>17 mm on 5/5/2005 on 5/5/2005 Completed 9 mo IAH on 2/20/2006</i>	LTBI Test Used: <input type="checkbox"/> TST <input type="checkbox"/> IGRA Round 1, Date tested: _____ Result: _____ mm of TST <i>N/A</i> Pos. Neg. Indeterminate/Borderline	CXR Date _____ Result: <input type="checkbox"/> Normal <input type="checkbox"/> Abnormal <input type="checkbox"/> Cavitory <input type="checkbox"/> Non Cav.	Case: Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> LTBI Tx Recommended: Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> If Yes: Tx Start: _____ Tx Stop: _____ Stop Reason: _____
DOB: <i>10/4/55</i> Race: <i>W</i> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Relationship: Household <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Close friend Last exposure date: <i>7/4/12</i>	Symptoms Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>		Round 2, Date tested: _____ Result: _____ mm of TST <i>N/A</i> Pos. Neg. Indeterminate/Borderline		Comments/Address if needed: <i>Round 1 to Rich - 8/15/12 Round 2 to Rich - 11/30/12</i>



Objectives Answered

65

- Describe 3 critical nurse case management decision points during TB treatment
- Explain the rationale for monitoring bacteriology culture conversion
- List 4 ongoing TB nurse cases management interventions that may improve treatment outcomes
- Explain criteria used for determining treatment completion

Where we Began: The Goals Nurse Case Management

66

Goals

- To cure the individual
- To minimize transmission of *Mycobacterium tuberculosis* to others



Upcoming TB Trainings in the Series

- Friday, April 26, 1-3 P.M. “TB Contact Investigation” – Denise Dodge and Paul Regan
- Friday, May 31, 10 A.M. – 12 P.M. – “Complex TB Cases” – Denise Dodge and Debbie Staley
- Unknown date and time – “The Odds and Ends”